NASDAQ-listed biopharmaceutical agency Atai Life Sciences says cryptocurrencies like Bitcoin may very well be key to survival for biotech startups as they wade via years of regulatory approvals.
Atai, which is growing psychological well being therapies utilizing psychedelics like DMT and MDMA, has change into the most recent public firm to announce plans to purchase Bitcoin.
It plans to purchase $5 million of Bitcoin (BTC), its founder and chair Christian Angermayer wrote in a March 20 Substack submit.
“Drug growth is a cash-hungry, long-term enterprise,” he stated. “The mandatory steps to realize regulatory approval can simply take greater than a decade.”
TechCrunch reported in January that, in keeping with a number of knowledge units, the variety of startups shutting down rose in 2024 in comparison with 2023 as corporations did not obtain extra funding to maintain operating.
Angermayer stated the approval course of is important for drug growth, however it exposes corporations to monetary dangers whereas sticky inflation and excessive rates of interest have triggered the present “biotech winter.”
Supply: Christian Angermayer
He added that the present trade method is to place money reserves in near-zero-yield accounts, as “preserving capital was extra vital than incomes a return on their money stability.”
“This context units the stage for contemplating unconventional treasury strikes — like including Bitcoin to the treasury — to deal with the dual threats of inflation and low-yielding reserves, and basically to optimize and maximize shareholder worth.”
Atai will be part of at the very least 5 different public medical firms which have purchased Bitcoin in latest months with the purpose of boosting shareholder returns.
Biotech agency Quantum BioPharma stated on March 20 that it had now spent $3.5 million in whole to purchase BTC and different cryptocurrencies after an preliminary $1 million funding in December.
Medical machine maker Semler Scientific stated final month that because it began in Might, it had spent a complete of $280.4 million shopping for 3,192 BTC.
Hoth Therapeutics, Acurx Prescribed drugs and Enlivex Therapeutics stated in separate statements on Nov. 20 that every of them would purchase $1 million in Bitcoin.
Associated: Michael Saylor’s Technique plans to supply 5M shares to purchase extra Bitcoin
Atai’s Angermayer stated his agency’s Bitcoin purchase would primarily be as a long-term inflation hedge but in addition a short-term diversification play. He added that Bitcoin is more likely to have short-term worth fluctuations, so the Berlin-based agency is holding largely US {dollars}, short-term securities, and shares for its desired run fee into 2027.
Atai’s $5 million put would imply it is ready to purchase simply over 59 BTC at its present worth of round $84,300 and make it the world’s 52nd largest holder amongst public corporations, in keeping with Bitbo knowledge.
Bitcoin has struggled to maintain afloat amid a wider market rout attributable to US President Donald Trump’s tariff threats and fears of a US recession, which Trump hasn’t dominated out.
Atai’s share worth rose early in March 20 buying and selling to a peak of $1.47 however tapered off to shut the day down 1.44% at $1.37, in accordance to Google Finance. Its inventory has sunk practically 93% from its mid-2021 public debut peak however is up 3% to date this yr.
Journal: Crypto followers are obsessive about longevity and biohacking — Right here’s why
